Rayos

(Prednisone)

ApprovedSmall molecule

Prednisone is a steroid medication that reduces inflammation and suppresses the immune system, used to treat conditions like allergies, asthma, arthritis, and certain autoimmune diseases.[2] Rayos is currently approved and in use across 293 indications[4].[1]

Rayos is one of 3104 small molecule programs targeting Glioma. It is currently in Approved.

293

Indications

1,213

Total Trials

Active Trials

3,103

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

CellulitisActive, not recruiting

Pyoderma GangrenosumActive, not recruiting

Chronic Rhinosinusitis Without Nasal PolypsActive, not recruiting

Acquired HemophiliaActive, not recruiting

Premature BirthApproved

HIV InfectionActive, not recruiting

HemangiomaActive, not recruiting

ColitisActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

GliomaPhase 3

Active, not recruiting

CellulitisPreclinical

Active, not recruiting

Pyoderma GangrenosumPhase 3

Active, not recruiting

Chronic Rhinosinusitis Without Nasal PolypsApproved

Active, not recruiting

Acquired HemophiliaPhase 2/Phase 3

Active, not recruiting

Premature BirthApproved

Approved

HIV InfectionPhase 2

Active, not recruiting

HemangiomaPhase 2

Active, not recruiting

ColitisPhase 2

Active, not recruiting

Systemic Lupus ErythematosusPhase 3

Active, not recruiting

Showing 10 of 290 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

1 2

Halaven

Eisai

Preclinical

38 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Acupan

YYonsei University

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Chirocaine

PPurdue Pharma LP

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Older Patients

NCT04594798

Phase 2Recruiting

Hepatocellular Carcinoma

NCT05901519

Phase 2Active, not recruiting

Prostate Cancer

NCT04262154

Phase 3Active, not recruiting

Idiopathic Nephrotic Syndrome

NCT05627557

Phase 1Active, not recruiting

Lymphoma

NCT02337985

Phase 1Active, not recruiting

Kidney Transplant

NCT03816332

Clinical

Trials by Indication[1]

Lymphoma33 trials

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Completed· Eisai logo

Eisai·Phase 2·NCT00211185·49 enrolled

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Withdrawn· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT02595242

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Recruiting·GGALIA AVRAHAMI·N/A·NCT02797717·2,200 enrolled

Show 30 more trials

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting·—·Phase 2·NCT03749018·30 enrolled

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Unknown status·SSun Yat-sen University·Phase 2·NCT03321890·102 enrolled

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00005089·71 enrolled

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Unknown status· Amgen logo

Amgen·Phase 2·NCT00005959

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00822120·371 enrolled

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028717·400 enrolled

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00302003·287 enrolled

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01920932·77 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 3·NCT00004112

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Completed·UUniversity of Chicago·Phase 1/2·NCT02213913·55 enrolled

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

Active, not recruiting·—·Phase 1·NCT02337985·10 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Unknown status·PPeking Union Medical College Hospital·Phase 1/2·NCT02987244·100 enrolled

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Suspended·—·Phase 2·NCT06692452·24 enrolled

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00169156·27 enrolled

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04061772·54 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004179·475 enrolled

Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

Withdrawn·—·N/A·NCT00110006

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Completed·EEmory University·Phase 1/2·NCT00634179·37 enrolled

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00217425·46 enrolled

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Recruiting·UUniversity of Rochester·Phase 2·NCT03758989·40 enrolled

Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Completed·UUnknown Sponsor·Phase 3·NCT00053768·392 enrolled

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003150·630 enrolled

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT01390584·6 enrolled

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Withdrawn·FFate Therapeutics·Phase 1·NCT05934097

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting·CCStone Pharmaceuticals·Phase 1·NCT05279300·480 enrolled

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Completed·NNorthwestern University·Phase 1·NCT03742258·12 enrolled

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04745949·31 enrolled

Prostate Cancer29 trials

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Terminated·CCostantine Albany·Phase 2·NCT01681433·72 enrolled

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Unknown status·FFudan University·Phase 2·NCT05223582·34 enrolled

Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01994590·4 enrolled

Show 26 more trials

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Active, not recruiting·MMayo Clinic·Phase 2·NCT05689021·8 enrolled

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04100018·1,030 enrolled

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Completed·UUniversity of Washington·Phase 2·NCT02849990·22 enrolled

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02985957·351 enrolled

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Completed·—·Phase 2·NCT01393730·40 enrolled

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Completed· Astellas logo

Astellas·Phase 1/2·NCT00514267·32 enrolled

Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Completed·WWeill Medical College of Cornell University·Phase 1·NCT00916123·15 enrolled

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Completed·AAchieve Life Sciences·Phase 3·NCT01578655·630 enrolled

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00544440·57 enrolled

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Withdrawn·BBaptist Health South Florida·Phase 1/2·NCT06329830

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Completed· Takeda logo

Takeda·Phase 1/2·NCT01666314·137 enrolled

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00087165·22 enrolled

AZD2171 to Treat Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00436956·59 enrolled

OGX-427 in Castration Resistant Prostate Cancer Patients

Completed·BBritish Columbia Cancer Agency·Phase 2·NCT01120470·74 enrolled

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04262154·28 enrolled

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

Completed·—·Phase 2·NCT03098836·93 enrolled

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Completed·LLatin American Cooperative Oncology Group·Phase 2·NCT02867020·128 enrolled

Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

Withdrawn·NNew Mexico Cancer Research Alliance·Phase 2·NCT01478308

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Completed·TTavanta Therapeutics·Phase 3·NCT04887506·107 enrolled

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Completed·AAchieve Life Sciences·Phase 3·NCT01188187·1,022 enrolled

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Recruiting· Astellas logo

Astellas·Phase 2·NCT02960022·900 enrolled

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

Completed·—·Phase 1·NCT01378091·64 enrolled

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT07225946·800 enrolled

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Terminated·EExelixis·Phase 3·NCT01522443·119 enrolled

Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.

Not yet recruiting·QQilu Hospital of Shandong University·Phase 2·NCT06500247·43 enrolled

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·MMacroGenics·Phase 2·NCT05848011·154 enrolled

Acute Lymphoblastic Leukemia18 trials

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00557193·218 enrolled

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Withdrawn·UUniversity of Washington·Phase 2·NCT02538926

Show 15 more trials

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02143414·53 enrolled

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00671034·166 enrolled

Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

Unknown status·TTongji Hospital·Phase 4·NCT02690922·40 enrolled

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01005758·180 enrolled

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002514·1,929 enrolled

Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT01230983·573 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT01117441·6,136 enrolled

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00494897·374 enrolled

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00390793·107 enrolled

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02003222·488 enrolled

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT00792948·97 enrolled

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT02036489·107 enrolled

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT01186328·6 enrolled

Multiple Myeloma8 trials

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00040937·147 enrolled

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00006890·67 enrolled

Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma

Terminated·BBasque Health Service·Phase 4·NCT02773550·24 enrolled

Show 5 more trials

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 1/2·NCT01335685·61 enrolled

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT01818752·955 enrolled

Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients

Terminated·FFondazione EMN Italy Onlus·Phase 2·NCT01116128·8 enrolled

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02474563·171 enrolled

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Completed·FFondazione EMN Italy Onlus·Phase 3·NCT00551928·402 enrolled

Diffuse Large B-Cell Lymphoma8 trials

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Recruiting·LLi Zhiming·Phase 2·NCT05422066·50 enrolled

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Terminated· Roche logo

Roche·Phase 3·NCT01287741·1,418 enrolled

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT01848132·121 enrolled

Show 5 more trials

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated·UUniversity of Nebraska·Phase 1·NCT00736450·37 enrolled

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 2·NCT04660799·50 enrolled

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03003520·46 enrolled

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Completed·—·Phase 1/2·NCT02073097·48 enrolled

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04978584·62 enrolled

83 more indications

Metastatic Prostate Cancer4 trials

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Completed·DDavid Oh·Phase 2·NCT03007732·23 enrolled

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Completed·GGroupe D'Etude des Tumeurs Uro-Genitales·Phase 2·NCT00627354·90 enrolled

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT03678025·1,273 enrolled

Show 1 more trial

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00331344·100 enrolled

Chronic Graft Versus Host Disease4 trials

Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity

Recruiting·BByung-Sik Cho·Phase 2·NCT06756061·88 enrolled

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00031824·82 enrolled

Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

Completed·SStanford University·Phase 2·NCT00388362·36 enrolled

Show 1 more trial

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

Completed·PPharmacyclics LLC.·Phase 3·NCT02959944·193 enrolled

Kidney Transplant3 trials

Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

Completed·MMedical University of South Carolina·N/A·NCT02954198·40 enrolled

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03816332·12 enrolled

Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients

Completed·AAssociação Médico Espírita de Botucatu·Phase 4·NCT02683291·48 enrolled

Follicular Lymphoma3 trials

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Withdrawn·SSecuraBio·Phase 2·NCT02605694

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06043323·20 enrolled

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting·UUniversity of Birmingham·Phase 2·NCT05848765·284 enrolled

Pneumonia2 trials

Corticosteroids in Community Acquired Pneumonia

Withdrawn·VVanderbilt University Medical Center·Phase 2·NCT04652414

Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19

Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT04534478·120 enrolled

Pregnancy2 trials

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

Unknown status·SShanghai First Maternity and Infant Hospital·Phase 4·NCT02990403·500 enrolled

The Clinical Features and Pregnancy Outcomes of CTD Patients

Recruiting·QQilu Hospital of Shandong University··NCT04918524·126 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

Not yet recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT07451665·180 enrolled

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Recruiting·RRuijin Hospital·Phase 2·NCT06803693·152 enrolled

Idiopathic Nephrotic Syndrome2 trials

Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study

Completed·NNanjing University School of Medicine·N/A·NCT02298335·235 enrolled

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05627557·85 enrolled

Multiple Sclerosis2 trials

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00014755·35 enrolled

Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis

Terminated·CClaudio Gobbi·Phase 4·NCT01411514·27 enrolled

Rheumatoid Arthritis2 trials

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

Completed·ZZalicus·Phase 2·NCT01369745·294 enrolled

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00634933·222 enrolled

Leukemia2 trials

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia

Unknown status·GGrupo Argentino de Tratamiento de la Leucemia Aguda·Phase 2/3·NCT00002499

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002494·134 enrolled

Asthma2 trials

DOSE Trial: Optimal Dose of Oral Corticosteroids to Treat Asthma Exacerbations

Not yet recruiting·AAndréanne Côté·Phase 4·NCT06833814·36 enrolled

Repeat Emergency Department Visits Among Patients With Asthma and COPD

Terminated·SState University of New York at Buffalo·N/A·NCT02499887·6 enrolled

Stem Cell Transplantation2 trials

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002599·750 enrolled

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·NNorthwestern University·Phase 1·NCT00004232

Duchenne Muscular Dystrophy2 trials

High-dose Prednisone in Duchenne Muscular Dystrophy

Completed·CCooperative International Neuromuscular Research Group·Phase 3·NCT00110669·64 enrolled

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

Withdrawn·—·Phase 2·NCT02036463

Acute Graft Versus Host Disease2 trials

A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

Terminated· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT04220632·1 enrolled

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00357084·53 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Tacrolimus1 trial

Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens

Completed· Astellas logo

Astellas·Phase 3·NCT00157014·111 enrolled

Elderly Patients1 trial

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL

Completed·FFondazione Italiana Linfomi - ETS·Phase 3·NCT01148446·226 enrolled

Respiratory tract infection1 trial

Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Terminated·MMaisonneuve-Rosemont Hospital·Phase 2·NCT01432080·12 enrolled

Neuroblastoma1 trial

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00033293·53 enrolled

Treatment1 trial

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

Optic Neuritis1 trial

Longitudinal Optic Neuritis Study (LONS)

Unknown status·NNational Eye Institute (NEI)·N/A·NCT00000147

Cancer of the Prostate1 trial

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate

Withdrawn·JJohn P. Fruehauf·Phase 2·NCT00598858

Hodgkin's Disease1 trial

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00005578·219 enrolled

First Line Therapy1 trial

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06660355·120 enrolled

Myocarditis1 trial

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

Completed·MMayo Clinic·Phase 2·NCT00004482·40 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01017939·34 enrolled

Langerhans Cell Histiocytosis1 trial

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

Recruiting·WWest China Second University Hospital·N/A·NCT07431060·120 enrolled

Polymyalgia Rheumatica1 trial

A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Terminated· Novartis logo

Novartis·Phase 2·NCT01364389·16 enrolled

Allograft1 trial

Belatacept Therapy for the Failing Renal Allograft

Completed·AAndrew B Adams·Phase 3·NCT01921218·13 enrolled

Recruiting·UUniversity of British Columbia·N/A·NCT06453447·40 enrolled

Toxicity1 trial

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03847649·60 enrolled

Drug1 trial

Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis

Completed·UUniversita di Verona·Phase 2/3·NCT00369356·375 enrolled

Colitis1 trial

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT04305145·42 enrolled

Efficacy1 trial

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Completed·CCelltrion·Phase 3·NCT02162771·140 enrolled

Thrombotic Thrombocytopenic Purpura1 trial

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Completed·OOhio State University·Phase 3·NCT00713193·26 enrolled

mCRPC1 trial

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Completed·RRahul Aggarwal·Phase 1/2·NCT02494921·43 enrolled

Older Patients1 trial

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Active, not recruiting·UUniversity of Rochester·Phase 2·NCT04594798·39 enrolled

Hepatocellular Carcinoma1 trial

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT05901519·20 enrolled

Telitacicept1 trial

Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

Unknown status·QQilu Hospital of Shandong University··NCT05644210·80 enrolled

Monoclonal1 trial

Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX

Completed· Astellas logo

Astellas·Phase 2·NCT00693524·94 enrolled

Fibrosis1 trial

Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial

Unknown status·UUniversity of Parma·Phase 3·NCT01240850·200 enrolled

Croup1 trial

Community Care for Croup (RCT)

Completed·WWashington University School of Medicine·Phase 4·NCT01042145·87 enrolled

Abiraterone Acetate1 trial

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Completed·AAstex Pharmaceuticals, Inc.·Phase 1/2·NCT01685268·49 enrolled

Chronic Kidney Disease1 trial

Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation

Suspended·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04844814·204 enrolled

Single Ascending Dose1 trial

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Completed·CCorcept Therapeutics·Phase 1·NCT03508635·130 enrolled

Glucocorticoids1 trial

Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids

Completed·VVanderbilt University Medical Center·Phase 1·NCT03023891·25 enrolled

Kidney Cancer1 trial

Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

Completed·UUniversity of New Mexico·Phase 2·NCT00003584·35 enrolled

Leber Congenital Amaurosis1 trial

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

Active, not recruiting·AAtsena Therapeutics Inc.·Phase 1/2·NCT03920007·15 enrolled

Nephropathy1 trial

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

Recruiting·MMayo Clinic·Phase 2·NCT06676579·16 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled

Prostate1 trial

Pazopanib, Docetaxel, Prednisone Prostate

Completed·—·Phase 1·NCT01385228·36 enrolled

Giant Cell Arteritis1 trial

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

Terminated· GSK logo

GSK·Phase 3·NCT02531633·161 enrolled

Vasculitis1 trial

The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children

Unknown status·—·Phase 3·NCT03692416·70 enrolled

Hemangioma1 trial

Randomized Study of Hormonal Regulation of Infantile Hemangioma

Completed·FFDA Office of Orphan Products Development·N/A·NCT00004436·30 enrolled

Bronchiolitis Obliterans1 trial

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Recruiting·—·Phase 2·NCT05922761·45 enrolled

Lymphoid Malignancies1 trial

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT05371054·8 enrolled

Hepatitis1 trial

Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis

Completed·IIndiana University·Phase 2·NCT04072822·147 enrolled

Urticaria1 trial

Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency

Completed·UUniversity Hospital, Toulouse·Phase 2/3·NCT02565680·100 enrolled

Inflammatory Bowel Disease1 trial

Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease

Completed·UUniversity of British Columbia·Phase 4·NCT01981889·53 enrolled

Liquid Biopsy1 trial

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Unknown status·FFudan University··NCT05188911·30 enrolled

Olverembatinib1 trial

Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05594784·79 enrolled

Lupus Nephritis1 trial

Rituximab and Belimumab for Lupus Nephritis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02260934·43 enrolled

Nephrotic Syndrome1 trial

The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children

Recruiting·JJianhua Zhou·Phase 4·NCT05772871·402 enrolled

Absorption1 trial

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06566989·8 enrolled

Hematologic Malignancies1 trial

Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)

Completed·—·Phase 1·NCT01888952·10 enrolled

B-cell acute lymphoblastic leukemia1 trial

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Completed·UUniversity of Washington·Phase 1·NCT03991884·24 enrolled

Chronic Lymphocytic Leukemia1 trial

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Completed·GGerman CLL Study Group·Phase 2·NCT00309881·75 enrolled

Chronic Rhinosinusitis1 trial

The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis

Completed·KKafrelsheikh University·Phase 2/3·NCT05931744·120 enrolled

Renal Transplant1 trial

Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients

Completed· Novartis logo

Novartis·Phase 4·NCT00419926·313 enrolled

Ulcerative Colitis1 trial

Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis

Terminated·GGrupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa·Phase 4·NCT02921555·75 enrolled

Cardiovascular1 trial

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

Withdrawn·UUniversity of Saskatchewan·Phase 4·NCT02058875

Heart Failure1 trial

Dose-comparison Study of Prednisone in Heart Failure

Completed·HHebei Medical University·Phase 3·NCT01559727·40 enrolled

Neuromyelitis Optica1 trial

Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT02809079·100 enrolled

Cardiomyopathy1 trial

Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.

Recruiting·MMedical University of Warsaw·Phase 4·NCT04654988·100 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

Active, not recruiting·TTianjin Medical University General Hospital·Phase 2/3·NCT06452537·102 enrolled

Bullous Pemphigoid1 trial

Efficacy and Safety of Omalizumab in Bullous Pemphigoid

Completed·UUniversity of Iowa·Phase 4·NCT00472030·2 enrolled

Deafness1 trial

Sudden Deafness Treatment Trial

Completed·MMassachusetts Eye and Ear Infirmary·Phase 3·NCT00097448·255 enrolled

Randomized1 trial

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Active, not recruiting·—·Phase 2·NCT03141671·345 enrolled

Thrombocytopenic Purpura1 trial

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

Completed·MMayo Clinic·Phase 1·NCT00486421·22 enrolled

Unspecified1 trial

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Withdrawn· GSK logo

GSK·Phase 1·NCT02380313

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

DELTASONE

NDA NDA009986

Jan 1, 1982

METICORTEN

NDA NDA009766

Jan 1, 1982

PARACORT

NDA NDA010962

Jan 1, 1982

PREDNISONE

NDA NDA017109

Jul 26, 2012

RAYOS

NDA NDA202020

Sources

References

[1]
ClinicalTrials.gov — 1213 trial records for Prednisone. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Rayos drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Prednisone compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Prednisone. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA202020). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Rayos. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Roxane Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: RRoxane Laboratories

Patent Landscape[6]

Patent Cliff

Aug 3, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9504699Aug 3, 2027

8168218Jan 7, 2028

Rayos

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Lymphoma33 trials

Prostate Cancer29 trials

Acute Lymphoblastic Leukemia18 trials

Multiple Myeloma8 trials

Diffuse Large B-Cell Lymphoma8 trials

Metastatic Prostate Cancer4 trials

Chronic Graft Versus Host Disease4 trials

Kidney Transplant3 trials

Follicular Lymphoma3 trials

Pneumonia2 trials

Pregnancy2 trials

Efficacy and Safety2 trials

Idiopathic Nephrotic Syndrome2 trials

Multiple Sclerosis2 trials

Rheumatoid Arthritis2 trials

Leukemia2 trials

Asthma2 trials

Stem Cell Transplantation2 trials

Duchenne Muscular Dystrophy2 trials

Acute Graft Versus Host Disease2 trials

Real-world Study1 trial

Tacrolimus1 trial

Elderly Patients1 trial

Respiratory tract infection1 trial

Neuroblastoma1 trial

Treatment1 trial

Optic Neuritis1 trial

Cancer of the Prostate1 trial

Hodgkin's Disease1 trial

First Line Therapy1 trial

Myocarditis1 trial

Metastatic Castration-Resistant Prostate Cancer1 trial

Langerhans Cell Histiocytosis1 trial

Polymyalgia Rheumatica1 trial

Allograft1 trial

Sts1 trial

Monotherapy1 trial

Radius Fracture1 trial

Toxicity1 trial

Drug1 trial

Colitis1 trial

Efficacy1 trial

Thrombotic Thrombocytopenic Purpura1 trial

mCRPC1 trial

Older Patients1 trial

Hepatocellular Carcinoma1 trial

Telitacicept1 trial

Monoclonal1 trial

Fibrosis1 trial

Croup1 trial

Abiraterone Acetate1 trial

Chronic Kidney Disease1 trial

Single Ascending Dose1 trial

Glucocorticoids1 trial

Kidney Cancer1 trial

Leber Congenital Amaurosis1 trial

Nephropathy1 trial

Acute Leukemia of Ambiguous Lineage1 trial

Prostate1 trial

Giant Cell Arteritis1 trial

Vasculitis1 trial

Hemangioma1 trial

Bronchiolitis Obliterans1 trial

Lymphoid Malignancies1 trial

Hepatitis1 trial

Urticaria1 trial

Inflammatory Bowel Disease1 trial

Liquid Biopsy1 trial

Olverembatinib1 trial

Lupus Nephritis1 trial

Nephrotic Syndrome1 trial

Absorption1 trial

Hematologic Malignancies1 trial

B-cell acute lymphoblastic leukemia1 trial